Peptides may become easier to obtain after RFK Jr.'s push

The FDA is set to consider easing restrictions on several peptide injections at a meeting expected in July after HHS Secretary Robert F. Kennedy Jr. urged greater access, and officials and experts have noted many peptides have not undergone full FDA safety review.

Federal health officials are preparing to discuss easing restrictions on several peptide injections at an FDA meeting expected in July. The discussion follows public advocacy from Health and Human Services Secretary Robert F. Kennedy Jr. for broader access to some peptides. Many peptides in circulation have not been fully reviewed by the FDA and federal advisories have cautioned about unapproved peptide treatments. Key facts: - HHS Secretary Robert F. Kennedy Jr. has publicly advocated making some peptides more accessible. - The FDA issued a federal notice identifying more than a half dozen peptide injections as candidates for inclusion on a list that would allow compounding by pharmacies. - An FDA meeting to consider relaxing limits on those peptides is expected in July. - Officials and experts have emphasized that most peptides have not undergone full FDA safety review and that prior FDA advisories recommended compounded drugs only when no approved alternative exists. Summary: If the FDA moves the identified peptides onto a compounding-allowed list, access through pharmacies would likely broaden while oversight and safety considerations would remain central to the debate. The FDA meeting is expected in July; outcomes are undetermined at this time.